mesalamine 1 g suppository
Selected indexed studies
- Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. (Inflamm Bowel Dis, 2010) [PMID:20310020]
- Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. (Inflamm Bowel Dis, 2005) [PMID:15973115]
- A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. (Dig Dis Sci, 2011) [PMID:20676771]
_Worker-drafted node — pending editorial review._
Connections
mesalamine 1 g suppository is a side effect of
Sources
- Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. (2010) pubmed
- Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. (2005) pubmed
- A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. (2011) pubmed
- Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis. (2019) pubmed
- Mesalazine-induced esophageal ulcers. A rare adverse effect. (2024) pubmed
- [Management of ulcerative colitis]. (2003) pubmed
- The role of aminosalicylates in the treatment of ulcerative colitis. (2002) pubmed
- Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. (1998) pubmed
- Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. (2012) pubmed
- Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. (2011) pubmed